OCA
XLO icon

Octagon Capital Advisors’s Xilio Therapeutics XLO Stock Holding History

Octagon Capital Advisors’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-127,500
Closed -$982K – 64
2023
Q4 		$982K Sell
127,500
-38,107
-23% -$754K 0.16% 30
2023
Q3 		$4.89M Sell
165,607
-7,607
-4% -$284K 0.75% 26
2023
Q2 		$6.35M Hold
173,214
– – 0.88% 22
2023
Q1 		$7.69M Hold
173,214
– – 1.11% 19
2022
Q4 		$6.52M Hold
173,214
– – 1.02% 22
2022
Q3 		$7.06M Buy
+173,214
New +$6.73M 1.22% 21

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Octagon Capital Advisors's XLO Position: Q1 2024 in Review

Octagon Capital Advisors sold out of Xilio Therapeutics (XLO) in Q1 2024, closing a stake of 127,500 shares — an estimated $982K sold.

Octagon Capital Advisors first reported a position in XLO in Q3 2022 and held it in 6 quarters. The position peaked at $7.69M in Q1 2023. 30 funds tracked by Wall St. Rank hold XLO as of Q1 2024.

  • Octagon Capital Advisors reported no remaining Xilio Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Octagon Capital Advisors sold 127,500 Xilio Therapeutics shares in Q1 2024, an estimated $982K.
  • Octagon Capital Advisors first reported a position in Xilio Therapeutics in Q3 2022 and held it in 6 quarters.
  • Octagon Capital Advisors's Xilio Therapeutics position peaked at $7.69M in Q1 2023.
  • 30 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2024.

Based on Octagon Capital Advisors's 13F filing for Q1 2024, filed 15 May 2024.